<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192566</url>
  </required_header>
  <id_info>
    <org_study_id>00004651</org_study_id>
    <nct_id>NCT03192566</nct_id>
  </id_info>
  <brief_title>Acetaminophen Dosing in Obese Adolescents</brief_title>
  <official_title>The Pharmacokinetics of Intravenous Acetaminophen and Its Metabolites in Obese Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's National Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although there are numerous studies investigating the pharmacokinetic properties of&#xD;
      intravenous acetaminophen in infants and children with normal weight, there are none in the&#xD;
      obese pediatric patient . This study will investigate the pharmacokinetics and&#xD;
      pharmacodynamics of acetaminophen (total Cl and Vd) in obese children and adolescents&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity represents one of the most important public health issues according to the World&#xD;
      Health Organization. It has reached epidemic proportions globally, with approximately 1.5&#xD;
      billion overweight adults aged 20 years and older and at least 600 million of them clinically&#xD;
      obese .Childhood obesity is particularly problematic, because the co morbid disease states&#xD;
      which accompany early obesity may require frequent pharmacotherapy and/or surgical&#xD;
      intervention. Many of the metabolic and cardiovascular complications of obesity may also be&#xD;
      present during childhood. Despite increased pharmacotherapy among obese patients, there is a&#xD;
      paucity of dosing guidelines for this population. Optimal drug dosing in obese pediatric&#xD;
      patients has not been explored as the present data available is specific for obese adults.&#xD;
      Acetaminophen is one of the most commonly used medications in pediatric patients.&#xD;
&#xD;
      Although there are numerous studies investigating the pharmacokinetic properties of&#xD;
      intravenous acetaminophen in infants and children with normal weight there are none in the&#xD;
      obese pediatric patient . This study will investigate the pharmacokinetics and&#xD;
      pharmacodynamics of acetaminophen (total clearance and volume of distribution in obese&#xD;
      children and adolescents&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Determine the single dose pharmacokinetics of acetaminophen and its metabolites (glucuronide, sulphate, cystein and mercapturic acid) in obese children and adolescents</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic clearance of acetaminophen and its metabolites (glucuronide, sulphate, cystein and mercapturic acid) in adolescent surgical patients</measure>
    <time_frame>up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate postoperative pain management using the numerical rating scale system.</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Obesity, Childhood</condition>
  <arm_group>
    <arm_group_label>Tylenol Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing of Tylenol for postoperative pain relief will include:&#xD;
children &lt; 16 years; 650 mg every 6 hours, max 2.6 gram per 24 hours and children &gt; or equal to 16 years every 6 hours 1 g of acetaminophen, max 4 gram per 24 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tylenol</intervention_name>
    <description>Dosing of Tylenol for post operative pain control</description>
    <arm_group_label>Tylenol Dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant will be a Children's National Health System (CNHS) inpatient or outpatient&#xD;
             admitted for at least 24 hours observation as part of the surgical plan of care.&#xD;
&#xD;
          -  Age range will be between 10 and 18.&#xD;
&#xD;
          -  BMI% will be calculated using height and weight and will include the 5th-85th% (normal&#xD;
             weight) and greater than or equal to 95th %.( obese weight)&#xD;
&#xD;
          -  ASA physical classification of I, II or III.&#xD;
&#xD;
          -  All racial and ethnic groups will be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient that is pregnant or lactating.&#xD;
&#xD;
          -  Renal insufficiency identified by GFR &lt;60 ml/min/1.73m2 and/or creatinine &gt; 3 times&#xD;
             upper limit of normal values&#xD;
&#xD;
          -  Liver disease identified by : AST, ALT, Î³-GT, bilirubin, albumin and AlkP and PT &gt; 3&#xD;
             times upper limit of normal values&#xD;
&#xD;
          -  Patients with Gilbert-Meulengracht Syndrome&#xD;
&#xD;
          -  Chronic alcohol intake or use of alcohol within last 72 hours&#xD;
&#xD;
          -  Patients who are treated with drugs know to effect CYP2E1(inhibition: dithiocarb and&#xD;
             disulfiram. Induction: isoniazid) and UGT (UDP-glucuronyltransferases) (induction:&#xD;
             estradiol-containing contraceptives, carbamazepine, phenobarbital, phenytoin,&#xD;
             mesuximide, oxcarbazepine, rifampicin, primidone, atazanavir / ritonavir, lopinavir /&#xD;
             ritonavir, olanzapine, retigabine , nevaripine, efavirenz, saquinavir, nelfinavir,&#xD;
             lamotrigine, felbamate, zonisamide, bupropion. Inhibition: valproic acid)&#xD;
&#xD;
          -  Diabetes mellitus type II patients&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Acetaminophen intake up to 24 hours before enrollment.&#xD;
&#xD;
          -  Acetaminophen allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Janelle Vaughns, MD</last_name>
    <phone>202-476-4165</phone>
    <email>jvaughns@childrensnational.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elaine Williams, PhD</last_name>
    <phone>2024762245</phone>
    <email>EFWillia@childrensnational.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Childrens National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janelle Vaughns, MD</last_name>
      <phone>202-476-4165</phone>
      <email>jvaughns@childrensnational.org</email>
    </contact>
    <contact_backup>
      <last_name>Elaine Williams, PhD</last_name>
      <phone>2024762245</phone>
      <email>EFWillia@childrensnational.org</email>
    </contact_backup>
    <investigator>
      <last_name>John N van den Anker, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012 Feb 1;307(5):491-7. doi: 10.1001/jama.2012.39. Epub 2012 Jan 17.</citation>
    <PMID>22253363</PMID>
  </results_reference>
  <results_reference>
    <citation>Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA. 2012 Feb 1;307(5):483-90. doi: 10.1001/jama.2012.40. Epub 2012 Jan 17.</citation>
    <PMID>22253364</PMID>
  </results_reference>
  <results_reference>
    <citation>Cali AM, Caprio S. Obesity in children and adolescents. J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S31-6. doi: 10.1210/jc.2008-1363. Review.</citation>
    <PMID>18987268</PMID>
  </results_reference>
  <results_reference>
    <citation>Erstad BL. Which weight for weight-based dosage regimens in obese patients? Am J Health Syst Pharm. 2002 Nov 1;59(21):2105-10. Review.</citation>
    <PMID>12434728</PMID>
  </results_reference>
  <results_reference>
    <citation>Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999 Jan;88(1):1-7. Review.</citation>
    <PMID>9874695</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet. 1993 Aug;25(2):103-14. Review.</citation>
    <PMID>8403734</PMID>
  </results_reference>
  <results_reference>
    <citation>Mohammed BS, Engelhardt T, Cameron GA, Cameron L, Hawksworth GM, Hawwa AF, McElnay J, Helms PJ, McLay JS. Population pharmacokinetics of single-dose intravenous paracetamol in children. Br J Anaesth. 2012 May;108(5):823-9. doi: 10.1093/bja/aes025. Epub 2012 Mar 1.</citation>
    <PMID>22389380</PMID>
  </results_reference>
  <results_reference>
    <citation>Zuppa AF, Hammer GB, Barrett JS, Kenney BF, Kassir N, Mouksassi S, Royal MA. Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. J Pediatr Pharmacol Ther. 2011 Oct;16(4):246-61. doi: 10.5863/1551-6776-16.4.246.</citation>
    <PMID>22768009</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's National Research Institute</investigator_affiliation>
    <investigator_full_name>Janelle Vaughns</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Acetaminophen</keyword>
  <keyword>Anesthesia</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

